What Is Generalized Anxiety Disorder (GAD)?

Worry is part of being human. Everyone worries. What separates generalized anxiety disorder from normal worry is not the presence of anxiety, but its persistence, its scope, and its refusal to respond to reason.

In GAD, the worry is not about one thing. It moves. Work, health, relationships, money, the commute, the weather, a text message someone didn’t reply to. It is chronic. It is present more days than not. It is difficult to control even when the person knows the worry is disproportionate. And it is accompanied by a body that has been running on low-grade stress for so long it no longer knows how to fully relax.

What This Page Covers

• What GAD is and how it is clinically defined
• How it differs from normal anxiety and other anxiety disorders
• The diagnostic criteria and the GAD-7 screening tool
• Physical and cognitive symptoms that often precede identification
• The full treatment pathway: therapy, medication, and combination
• Why continuous monitoring matters for GAD

The Scope of GAD

An estimated 2.7% of U.S. adults had GAD in the past year. An estimated 5.7% of U.S. adults experience GAD at some time in their lives. Past-year prevalence is higher for women (3.4%) than for men (1.9%). GAD affects 6.8 million U.S. adults, yet only 43.2% are receiving treatment.

GAD is one of the most common anxiety disorders seen in primary care and psychiatry, yet it is frequently undertreated. The chronic, diffuse nature of the symptoms means people often normalize them as part of who they are rather than recognizing them as a clinical condition with effective treatments.

What GAD Is: The Clinical Definition

GAD is characterized by excessive anxiety and worry about a variety of events or activities that occurs more days than not, for at least 6 months. People with GAD find it difficult to control their worry.

The worry in GAD is not focused on one specific fear like contamination (OCD), humiliation in public (social anxiety disorder), or unexpected panic (panic disorder). It is broad, shifting, and persistent. Common worries include work and family responsibilities, money, health, safety, and daily logistics. The focus often shifts over time.

For a clinical diagnosis, the worry must also be accompanied by at least three of the following six symptoms in adults (one in children): restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. These symptoms must significantly interfere with social, academic, or occupational functioning.

What GAD Feels Like

The clinical criteria describe what is measurable. What the experience actually feels like is something different.

People with GAD often describe a background hum of worry that is always there. Difficulty being fully present because the mind keeps jumping forward to worst-case scenarios. A body that feels perpetually tense, often most noticeable in the jaw, shoulders, and neck. Fatigue from the constant expenditure of nervous energy. Sleep that does not come easily because the worrying intensifies the moment external demands are removed.

Many people with GAD have had these symptoms for so long that they have normalized them. They call it their personality: “I am just a worrier.” The clinical language shifts that framing. This is a chronic anxiety condition that responds to treatment. The fact that it has been present for years does not make it untreatable. It makes it more important to treat.

How GAD Differs From Other Anxiety Disorders

Anxiety takes many clinical forms, and distinguishing them matters because the treatment emphasis shifts:

GAD vs. normal worry: Normal anxiety is proportionate to a specific stressor and resolves when the stressor passes. GAD worry is excessive relative to the situation, difficult to control, present across multiple domains simultaneously, and persistent even when things are objectively okay.

GAD vs. panic disorder: Panic disorder involves discrete, acute panic attacks and fear of future attacks. GAD involves chronic, diffuse, lower-level worry rather than episodic panic. Both can co-occur.

GAD vs. social anxiety disorder: Social anxiety centers specifically on fear of social evaluation and humiliation. GAD worry roams across many domains. A person with social anxiety is not worried about their car, their health, and their finances simultaneously in the same persistent way.

GAD vs. depression: GAD and major depressive disorder (MDD) frequently co-occur. 59% of people with GAD also meet criteria for MDD. When both are present, outcomes are generally worse than with either alone, and treatment typically needs to address both.

The GAD-7: What Clinicians Use to Screen

The Generalized Anxiety Disorder 7-item questionnaire (GAD-7) is the primary validated screening tool for GAD. The GAD-7 has been validated as both a diagnostic screening tool and a severity assessment scale. It asks about the past two weeks and covers seven core GAD symptoms, each scored from 0 (not at all) to 3 (nearly every day).

The GAD-2 and GAD-7 are two-item and seven-item validated screening tools for GAD. Scores of 5, 10, and 15 represent thresholds for mild, moderate, and severe anxiety. A score of 10 or higher is the standard clinical threshold for further evaluation and consideration of treatment.

A positive GAD-7 score prompts a clinical interview to confirm the diagnosis, assess severity and duration, screen for comorbid conditions, and rule out medical causes. Thyroid dysfunction and certain medications can produce anxiety symptoms that mimic GAD.

Who Is at Higher Risk

Several factors increase the likelihood of developing GAD:

• Women are approximately twice as likely to develop GAD as men.
• Family history of anxiety disorders
• Median age of onset is around 31, with a bimodal distribution, appearing in late teens to early twenties and again in the 30s and 40s.
• History of childhood anxiety or significant stressors
• Comorbid medical conditions that create ongoing uncertainty or physical symptoms
• Major life transitions (new job, relationship changes, health challenges)

Treatment Pathways for GAD

GAD is a chronic condition. It does not typically resolve with a single course of treatment. The clinical goal is not eliminating worry, which is neither realistic nor the point, but reducing its intensity and persistence to levels that no longer significantly impair functioning.

Cognitive Behavioral Therapy

CBT is the most evidence-based psychotherapy for GAD. It works by helping people identify the worry patterns that fuel anxiety, test the accuracy of catastrophic thinking, and develop tolerance for uncertainty rather than compulsively seeking reassurance. A 2024 network meta-analysis in JAMA Psychiatry of randomized clinical trials found CBT among the most effective psychotherapies for GAD. The effects are durable beyond the treatment period.

SSRIs and SNRIs

SSRIs and SNRIs are the first-line medication treatments for GAD. SSRIs are generally the preferred first choice, with SNRIs as an alternative. Symptom improvement typically appears within 3 to 6 weeks. Escitalopram and sertraline are among the most commonly used SSRIs for GAD. Duloxetine and venlafaxine are FDA-approved SNRIs for GAD.

One important consideration: SSRIs and SNRIs can temporarily increase anxiety in the first 1 to 2 weeks of treatment. This is a known pharmacological effect, not a sign that the medication is wrong. It is one of the most common reasons people discontinue early. Your prescriber should flag this before you start.

Buspirone

Buspirone is FDA-approved specifically for GAD. It is not habit-forming, does not carry the dependence risk of benzodiazepines, and does not produce sedation. It is commonly used as an adjunctive treatment with SSRIs or SNRIs for GAD. The limitation is timeline: buspirone takes 2 to 4 weeks to reach therapeutic effect. It is not useful for acute anxiety relief.

What About Benzodiazepines?

Benzodiazepines provide rapid relief of acute anxiety symptoms. But for chronic GAD management, they are not recommended as a first-line or sustained treatment. Current guidelines cite adverse effects including sedation and impaired cognition, risk of physical dependence, and higher mortality with long-term use as reasons to avoid benzodiazepines for chronic anxiety.

For a person in acute distress who needs a bridge while an SSRI takes effect, a short-term, time-limited benzodiazepine course may be part of a prescriber’s plan. As an ongoing first choice for GAD management, the evidence does not support it.

Combined Treatment

For moderate to severe GAD, combined treatment (SSRIs plus CBT) consistently outperforms either alone. Medication can reduce baseline anxiety to a level where the cognitive and behavioral work of CBT is more accessible. CBT produces durable changes that extend beyond medication use.

Why Ongoing Monitoring Matters

GAD has a chronic course. The disorder tends to wax and wane over the lifespan, and rates of full remission are low. This means the clinical picture needs to be monitored over time, not just at initial evaluation.

Most people with GAD are seen for a quarterly 15-minute appointment. Side effects that develop in the first weeks, changes in stress exposure that require dose adjustment, or early signs of emerging depression alongside GAD all require clinical contact before they compound.

SiggyMD’s daily check-in model provides continuous data to the prescriber between appointments. For people managing GAD with medication, this means side effects are caught early, dose adjustments happen when they are still effective, and the clinical picture your prescriber sees is current, not a retrospective summary three months later.

“GAD is the condition where I most wish I had daily data between appointments,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “The anxiety level changes based on what is happening in someone’s life. When I only see a patient quarterly, I’m adjusting based on a 10-minute summary of three months of their nervous system. That is a very incomplete picture. Daily check-ins change what is actually clinically possible.”

For people looking to understand the medication options available for anxiety, read our guide on what anxiety medication is best for your situation. To start your anonymous intake with a licensed prescriber who can review your full clinical picture, begin your SiggyMD intake.

What Members Are Saying

A.K., 36

Generalized Anxiety Disorder

“I thought I was just a worrier. Everyone in my family was a worrier. It didn’t occur to me that there was a name for what I was experiencing, or that it responded to treatment. My prescriber asked me the GAD-7 questions and within five minutes said she was seeing a clear clinical picture. Starting treatment was like turning down a noise I hadn’t known was there.”

D.R., 41

GAD with Depression

“I’d been on an antidepressant for the depression, but nobody had identified that I had GAD on top of it. The two were compounding each other. When we addressed both in treatment, the overall outcome was better than anything I’d gotten treating just one.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

Sources

1. NIMH. Generalized Anxiety Disorder. National Institute of Mental Health. Accessed June 2026.

2. PMC. A Comprehensive Review of the Generalized Anxiety Disorder. 2023.

3. Merck Manual Professional Edition. Generalized Anxiety Disorder. Updated 2024.

4. StatPearls / NCBI Bookshelf. Generalized Anxiety Disorder. Updated 2023.

5. American Family Physician. Generalized Anxiety Disorder and Panic Disorder in Adults. 2022.

6. Cleveland Clinic. Generalized Anxiety Disorder (GAD): Symptoms & Treatment. Accessed June 2026.

7. Garakani A, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Pharmacology. 2021;12:628416.

8. PsychDB. Generalized Anxiety Disorder (GAD). Accessed June 2026.

9. Papola D, et al. Psychotherapies for Generalized Anxiety Disorder in Adults. JAMA Psychiatry. 2024;81(3):250-259.